+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "JAK Inhibitor"

Asia Pacific Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027 - Product Thumbnail Image

Asia Pacific Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

  • Report
  • October 2021
  • 124 Pages
  • Asia Pacific
From
North America Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027 - Product Thumbnail Image

North America Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

  • Report
  • October 2021
  • 110 Pages
  • North America
From
Europe Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027 - Product Thumbnail Image

Europe Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

  • Report
  • October 2021
  • 125 Pages
  • Europe
From
LAMEA Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027 - Product Thumbnail Image

LAMEA Inflammatory Bowel Disease Treatment Market By Type, By Distribution Channel, By Route of Administration, By Drug Class, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

  • Report
  • October 2021
  • 124 Pages
  • Middle East, Africa
From
KOL Perspectives: Upadacitinib for Rheumatoid Arthritis - Product Thumbnail Image

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

  • Report
  • August 2018
  • 24 Pages
  • Global
From
Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028 - Product Thumbnail Image

Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028

  • Report
  • February 2020
  • 150 Pages
  • Asia Pacific
From
Immunology Drugs Market Report Suite for the United States - 2018-2024 - Product Thumbnail Image

Immunology Drugs Market Report Suite for the United States - 2018-2024

  • Report
  • April 2018
  • United States
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Tyrosine Kinase JAK Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type - Product Thumbnail Image

Tyrosine Kinase JAK Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • January 2024
  • 114 Pages
  • Global
From
Inflammatory Bowel Disease Drugs Market By Type, By Drug Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031 - Product Thumbnail Image

Inflammatory Bowel Disease Drugs Market By Type, By Drug Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • Report
  • July 2022
  • 274 Pages
  • Global
From
Loading Indicator

The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications. The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more